| Business Summary | | Cohesion
Technologies,
Inc.
is
focused
on
developing
and
commercializing
proprietary
surgical
products,
including
bioresorbable
hemostatic
devices
and
biosealants
for
tissue
repair
and
regeneration,
which
increase
the
effectiveness
of,
and
minimize
complications
following,
open
and
minimally
invasive
surgeries.
CoStasis
Surgical
Hemostat,
the
Company's
hemostatic
product,
is
designed
for
use
in
cardiovascular,
orthopedic
and
general
surgery
indications.
The
Company's
CoSeal
Surgical
Sealant,
its
lead
biosealant
product
candidate,
is
designed
for
sealing
vascular
grafts
and
other
tissues.
The
Company
received
European
Community
certification
for
CoStasis
in
fiscal
1999,
and
in
June
2000,
the
Company
received
approval
from
the
FDA
to
market
CoStasis
in
the
United
States.
The
Company
received
CE
Mark
in
February
2000
for
CoSeal
Surgical
Sealant
and
is
currently
conducting
clinical
trials
in
the
United
States. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cohesion
Technologies,
Inc.
develops
and
commercializes
proprietary
surgical
products
for
tissue
repair
and
regeneration
which
increase
the
effectiveness
of
and
minimize
complications
following
invasive
surgeries.
For
the
fiscal
year
ended
6/30/01,
revenues
rose
19%
to
$3
million.
Net
loss
before
acct.
change
totalled
$12.1
million,
vs.
an
income
of
$8.9
million.
Results
reflect
increased
Costasis
sales
which
commenced
in
7/00,
offset
by
decreased
gains
on
investments. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| John Daniels, M.D., 62 Chairman | -- | -- | David Foster, 43 CEO,
Director | $194K | $47K | Frank DeLustro, Ph.D., 52 Pres,
COO, Director | 194K | 164K | Deborah Webster, 41 VP
and CAO | 167K | 25K | Russell McDaniell, 51 VP
of Sales | 163K | -- | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|